User login
Treatment of high LDL saves lives of those with diabetes or cardiovascular disease
Hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) therapy that effectively reduces low-density lipoprotein (LDL) cholesterol increases life expectancy at least as much among those with diabetes mellitus without cardiovascular disease as among those with established cardiovascular disease alone.
While this result is only based on a validated theoretical model, it was extrapolated to the entire American population, and is consistent with randomized clinical trials. Public health programs and health care providers should give as much emphasis to treating elevated LDL among those with diabetes who are still free of cardiovascular disease as among those with already established cardiovascular disease.
Hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) therapy that effectively reduces low-density lipoprotein (LDL) cholesterol increases life expectancy at least as much among those with diabetes mellitus without cardiovascular disease as among those with established cardiovascular disease alone.
While this result is only based on a validated theoretical model, it was extrapolated to the entire American population, and is consistent with randomized clinical trials. Public health programs and health care providers should give as much emphasis to treating elevated LDL among those with diabetes who are still free of cardiovascular disease as among those with already established cardiovascular disease.
Hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) therapy that effectively reduces low-density lipoprotein (LDL) cholesterol increases life expectancy at least as much among those with diabetes mellitus without cardiovascular disease as among those with established cardiovascular disease alone.
While this result is only based on a validated theoretical model, it was extrapolated to the entire American population, and is consistent with randomized clinical trials. Public health programs and health care providers should give as much emphasis to treating elevated LDL among those with diabetes who are still free of cardiovascular disease as among those with already established cardiovascular disease.